Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$16.78
-0.7%
$15.45
$9.57
$30.41
$2.32B0.931.55 million shs800,545 shs
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
$218.96
$218.59
$87.07
$219.57
$6.86B2.15899,771 shsN/A
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$42.98
-1.4%
$35.24
$23.95
$52.34
$6.84B0.231.60 million shs1.34 million shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$18.22
+0.1%
$35.34
$16.88
$154.90
$1.79B0.452.19 million shs2.48 million shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$294.57
-0.2%
$301.21
$266.98
$417.82
$13.28B0.53445,641 shs284,212 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
0.00%+4.35%+1.94%+57.12%-33.07%
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
0.00%+7.99%+21.96%+58.66%-5.75%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.00%+6.46%-53.55%-66.53%-88.10%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
0.00%+3.62%-7.86%+0.72%-5.30%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
3.9445 of 5 stars
3.42.00.03.42.82.50.0
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
4.6791 of 5 stars
4.42.00.03.03.33.30.6
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
4.7381 of 5 stars
4.22.00.04.22.41.71.9
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
4.9954 of 5 stars
4.35.00.04.62.93.32.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
2.75
Moderate Buy$43.71160.51% Upside
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
0.00
N/AN/AN/A
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
2.78
Moderate Buy$58.2535.53% Upside
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
2.44
Hold$60.88234.20% Upside
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
2.69
Moderate Buy$386.1531.09% Upside

Current Analyst Ratings Breakdown

Latest ARWR, UTHR, IONS, SRPT, and GWPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$51.00 ➝ $57.00
6/30/2025
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$410.00 ➝ $385.00
6/26/2025
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
6/25/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Sell
6/20/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$123.00 ➝ $45.00
6/20/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform
6/18/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$85.00 ➝ $40.00
6/18/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$24.00
6/17/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$50.00 ➝ $25.00
6/17/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$29.00
6/17/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$60.00 ➝ $30.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$3.55M652.77N/AN/A$1.54 per share10.90
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
$311.33M22.05$0.01 per share18,588.22$23.48 per share9.33
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$705M9.70N/AN/A$3.73 per share11.52
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$1.90B0.94$2.43 per share7.49$15.99 per share1.14
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$2.88B4.62$28.41 per share10.37$144.34 per share2.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$599.49M-$1.40N/AN/A19.75N/A-45.33%-12.49%8/6/2025 (Estimated)
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
-$9.02M-$0.24N/A608.22N/A-11.05%-7.46%-6.13%N/A
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
-$453.90M-$2.99N/AN/AN/A-63.65%-91.85%-15.77%7/30/2025 (Estimated)
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$235.24M-$2.69N/A1.66N/A-11.12%-14.88%-5.12%8/6/2025 (Estimated)
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$1.20B$25.0611.7510.726.4540.44%19.33%16.73%7/30/2025 (Estimated)

Latest ARWR, UTHR, IONS, SRPT, and GWPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$6.89N/AN/AN/A$802.13 millionN/A
5/12/2025Q2 2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$0.06$2.75+$2.81$2.75$116.27 million$542.71 million
5/6/2025Q1 2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$2.20-$3.42-$5.62-$4.60$685.75 million$744.86 million
4/30/2025Q1 2025
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
-$1.07-$0.93+$0.14-$0.93$144.31 million$132.00 million
4/30/2025Q1 2025
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$6.29$6.63+$0.34$6.63$726.82 million$794.40 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
N/AN/AN/AN/AN/A
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
N/AN/AN/AN/AN/A
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
N/AN/AN/AN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
N/AN/AN/AN/AN/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
0.31
5.15
5.15
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
0.01
5.13
4.31
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
2.63
9.66
9.62
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1.00
4.02
2.46
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/A
5.46
5.23
CompanyEmployeesShares OutstandingFree FloatOptionable
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
400138.10 million132.16 millionOptionable
GW Pharmaceuticals plc stock logo
GWPH
GW Pharmaceuticals
1,16131.35 millionN/AOptionable
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
1,069159.16 million155.02 millionOptionable
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1,37298.28 million90.71 millionOptionable
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
1,30545.11 million40.46 millionOptionable

Recent News About These Companies

United Therapeutics Corporation (UTHR) - Yahoo Finance
UTHR United Therapeutics Corporation - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Arrowhead Pharmaceuticals stock logo

Arrowhead Pharmaceuticals NASDAQ:ARWR

$16.78 -0.12 (-0.71%)
Closing price 07/3/2025 03:44 PM Eastern
Extended Trading
$16.78 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

GW Pharmaceuticals stock logo

GW Pharmaceuticals NASDAQ:GWPH

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.

Ionis Pharmaceuticals stock logo

Ionis Pharmaceuticals NASDAQ:IONS

$42.98 -0.61 (-1.40%)
Closing price 07/3/2025 02:44 PM Eastern
Extended Trading
$42.64 -0.34 (-0.79%)
As of 07/3/2025 04:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Sarepta Therapeutics stock logo

Sarepta Therapeutics NASDAQ:SRPT

$18.22 +0.03 (+0.14%)
Closing price 07/3/2025 03:55 PM Eastern
Extended Trading
$18.22 0.00 (0.00%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

United Therapeutics stock logo

United Therapeutics NASDAQ:UTHR

$294.57 -0.65 (-0.22%)
Closing price 07/3/2025 02:47 PM Eastern
Extended Trading
$294.57 0.00 (0.00%)
As of 07/3/2025 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.